2m 2m 2m 2m 2m 2m 2m
- $500.9MMarket Cap
- 114.04%1-Year Change
- Medical Care FacilitiesIndustry
Oncology Inst (TOI)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 73
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call
The Oncology Institute, Inc. (NASDAQ: TOI) announced it will release its first quarter 2026 financial results on May 7, 2026, followed by a conference call at 5:30 p.m. ET. The company also recently achieved $1.8 million in Medicare savings in the CMS Enhancing Oncology Model Performance Period 3, marking significant period-over-period improvement.
04/27/2026, 9:00 AM • GlobeNewswire
U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care
M33 Growth, a Boston-based venture firm, announced a partnership with U.S. Neurology Associates (USNA), a physician services organization focused on community-based neurology care. Nitin Jain will serve as CEO and Brad Hively as Chairman. USNA aims to provide comprehensive, integrated neurological care including in-office infusions, diagnostics, and clinical trials while reducing operational burdens on physicians and delivering cost-effective solutions to patients and payers.
01/09/2026, 4:45 PM • GlobeNewswire
The Oncology Institute Announces Leadership Promotions
The Oncology Institute promoted Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. Panda brings 25+ years of IT and digital transformation experience from roles at Cisco and Infosys, while Mariano brings 18 years of People Operations experience. The promotions support TOI's growth in value-based cancer care and technology-enabled care delivery.
01/09/2026, 8:00 AM • GlobeNewswire
The Oncology Institute (TOI) has seen a massive stock rally of over 950% in 2025, driven by its value-based cancer care approach, AI-driven operational efficiencies, and potential for growth across multiple states.
11/21/2025, 5:20 AM • The Motley Fool
Oncology Institute Sales Jump 22 Percent
The Oncology Institute reported Q2 2025 revenue of $119.8 million, a 21.5% year-over-year increase, driven by strong pharmacy segment performance. Despite revenue growth, the company continues to face challenges with net losses and cash burn.
08/13/2025, 7:06 PM • The Motley Fool
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Key Executives
- Daniel Virnich FACHE
- Yale D. Podnos
- Robert Carter
- Mark Hueppelsheuser
- Stephen Cella
Current Ownership Distribution
- Institutions410.2M (72.19%)
- Mutual Funds109.5M (19.27%)
- Insiders48.5M (8.54%)
- Other0 (0.00%)